<DOC>
	<DOCNO>NCT02826161</DOCNO>
	<brief_summary>This international , multi-center , prospective , randomize , open-label Phase 3 clinical trial cancer stemness inhibitor napabucasin administer weekly paclitaxel versus weekly paclitaxel alone patient advance non-squamous non-small cell lung cancer disease progression follow systemic treatment platinum-based combination regimen metastatic setting , receive treatment immune checkpoint inhibitor candidate , additional approve therapy , weekly paclitaxel acceptable treatment option .</brief_summary>
	<brief_title>A Study Napabucasin ( BBI-608 ) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone Patients With Advanced , Previously Treated , Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Key Must histologically cytologically confirm nonsquamous NSCLC . Must progress follow treatment platinumbased combination chemotherapy metastatic disease , patient EGFR ALK/ROS1 genetic aberration must receive appropriately targeted treatment . Must receive either nivolumab pembrolizumab different INDapproved antiPD1 antiPDL1 therapy , unless medically contraindicate Weekly paclitaxel must acceptable treatment option Must submit tumor tissue correlative analysis Women childbearing potential partner woman childbearing potential must take measure avoid pregnancy receive period time follow protocol therapy Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , adequate organ function , life expectancy ≥ 3 month Key Has squamous NSCLC Has receive prior systemic treatment taxane advanced/metastatic disease Has receive systemic anticancer therapy within 14 day prior randomization Has receive radiotherapy within 28 day prior randomization , exception palliative radiotherapy focal lesion pain symptom control Has brain metastasis evolve neurologic symptom steroid requirement . Has major surgery require general anesthesia and/or mechanical ventilation within 28 day prior randomization Has correct QT interval ( QTc ) &gt; 470 m electrocardiogram ( ECG ) new abnormal finding clinically significant Has peripheral neuropathy ≥ Grade 2 ( NCICTCAE ) Refuses complete quality life questionnaires either alone assistance study staff despite adequate fluency Has intercurrent ( nonmalignant ) chronic medical psychiatric illness condition ( ) optimally control carry moderate high risk interfere protocol therapy administration compliance required procedure , judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Bronchial Neoplasms</keyword>
</DOC>